Kidney Cancer Trial, Recruiting NCT03747133 Sponsor: University Health Network, Toronto Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT03747133
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a solid kidney mass (either a primary kidney cancer or a cancer that has spread to the kidney) that measures 6cm or smaller and is suitable for a targeted radiation treatment called SABR
  • People who have been diagnosed with a kidney tumour, either confirmed by a tissue sample or identified through imaging scans
  • People who are not able to have surgery, either because surgery carries too high a risk for them or because they have chosen not to have surgery
  • People with a general health and activity level rated between 0 and 3 on a standard medical scale, meaning they may have some limitations but are not completely unable to care for themselves (confirm with trial site)

Who may not be able to join:

  • People who have 5 or more active areas of cancer spread in the body
  • People who have received systemic cancer treatment (such as chemotherapy or immunotherapy, though hormone therapy is an exception) within the 60 days before starting SABR
  • People who have previously had radiation treatment to the abdomen in a way that would overlap with the current treatment area and deliver too high a dose to the affected kidney
  • People with advanced kidney failure rated above stage 4 under standard kidney disease guidelines
  • People with certain inherited conditions, including Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary kidney cancer, or Tuberous Sclerosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rachel Glicksman, MD, The Princess Margaret Cancer Foundation

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2018
Est. completion
1 November 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

To evaluate the radiation induced renal impairments in patients receiving SABR.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov